These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 7466030)

  • 1. [Recent data about prostatic carcinoma (author's transl)].
    Coune A
    Rev Med Brux; 1980 May; 1(5):311-4. PubMed ID: 7466030
    [No Abstract]   [Full Text] [Related]  

  • 2. [Neuroendocrine differentiation in adenocarcinoma of prostate during combined androgen blockade therapy: a case report].
    Kitamoto K; Hayashi T; Tamada S; Ezaki K; Kawashima H; Sugimura K; Nakatani T
    Hinyokika Kiyo; 2005 Jan; 51(1):33-5. PubMed ID: 15732339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radical prostatectomy and early adjuvant hormonal therapy for pTxN+ adenocarcinoma of the prostate.
    Seay TM; Blute MC; Zincke H
    Urology; 1997 Dec; 50(6):833-7. PubMed ID: 9426709
    [No Abstract]   [Full Text] [Related]  

  • 4. [Carcinoma of the breast under estrogen-treatment for prostatic carcinoma (author's transl)].
    Bülow H; Wullstein HK; Böttger G; Schröder FH
    Urologe A; 1973 Sep; 12(5):249-53. PubMed ID: 4357698
    [No Abstract]   [Full Text] [Related]  

  • 5. Prostatic adenocarcinoma following androgen deprivation therapy: the new difficulty in histologic interpretation.
    Bostwick DG
    Anat Pathol; 1998; 3():1-16. PubMed ID: 10389579
    [No Abstract]   [Full Text] [Related]  

  • 6. [Clinical significance of nuclear DNA contents in prostate cancer].
    Fujimoto Y
    Nihon Gan Chiryo Gakkai Shi; 1988 Jun; 23(6):1265-76. PubMed ID: 3230343
    [No Abstract]   [Full Text] [Related]  

  • 7. What is the best postoperative treatment for patients with pT3bN0M0 adenocarcinoma of the prostate?
    Kasibhatla M; Peterson B; Anscher MS
    Prostate Cancer Prostatic Dis; 2005; 8(2):167-73. PubMed ID: 15711603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Neuroendocrine differentiation and metastasized to brain stem, intraorbit and base of tongue in prostate cancer during hormonal treatment: a case report].
    Sugi M; Yanishi M; Shimada O; Kawakita S; Murota T; Shikata N
    Hinyokika Kiyo; 2008 May; 54(5):373-6. PubMed ID: 18546865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Neuroendocrine differentiation in adenocarcinoma of the prostate during hormonal treatment: a case report].
    Matsumoto Y; Mibu H; Kagebayashi Y
    Hinyokika Kiyo; 2004 Nov; 50(11):813-5. PubMed ID: 15628545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. This paper evaluates the natural history of prostate cancer in heterogeneous cohort of men treated with HT.
    Yossepowitch O
    Eur Urol; 2007 Aug; 52(2):453. PubMed ID: 17674435
    [No Abstract]   [Full Text] [Related]  

  • 11. Despite PSA screening and the control by radical prostatectomy, patients treatment fails and have a PSA recurrence.
    Lotan Y
    Eur Urol; 2007 Aug; 52(2):453-4. PubMed ID: 17674436
    [No Abstract]   [Full Text] [Related]  

  • 12. [Hormone refractory prostate carcinoma metastasizes to the penis: a case report].
    Kawahara T; Manabe Y; Asazuma A; Aoyama T; Hashimura T
    Hinyokika Kiyo; 2009 Oct; 55(10):627-9. PubMed ID: 19938335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proptosis--an uncommon presentation of orbital metastases secondary to prostate cancer.
    Vissamsetti B; McArdle PA; Adams CJ; Hotiana Z; Morton AL; Alexander RJ
    Urol Int; 2007; 79(4):374-5; discussion 375. PubMed ID: 18025861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Loss of differentiation of a prostate adenocarcinoma after hormone therapy: the example of a metastasis in the spongy body of the penis].
    Uphoff J; Woziwodzki J; Schattka SO; Kollias A
    Aktuelle Urol; 2008 Sep; 39(5):373-7. PubMed ID: 18798127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate tumor biology and cell kinetics--theory.
    Coffey DS; Isaacs JT
    Urology; 1981 Mar; 17(Suppl 3):40-53. PubMed ID: 7010755
    [No Abstract]   [Full Text] [Related]  

  • 16. [Monotherapy with casodex at a dose of 150 mg--a new method of hormonal treatment of disseminated prostatic cancer].
    Rusakov IG; Alekseev BIa
    Urologiia; 2002; (5):23-6. PubMed ID: 12402771
    [No Abstract]   [Full Text] [Related]  

  • 17. [Brain metastasis of prostatic cancer: regression under hormonal treatment].
    Ameur A; Touiti D; el Mostarchid B; el Alami M; Jira H; Abbar M
    Prog Urol; 2001 Dec; 11(6):1298-301. PubMed ID: 11859670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical and biological study of androgen independent prostate cancer (AI PCa).
    Logothetis CJ; Hoosein NM; Hsieh JT
    Semin Oncol; 1994 Oct; 21(5):620-9. PubMed ID: 7524155
    [No Abstract]   [Full Text] [Related]  

  • 19. [Proton hypophysectomy and subtotal body irradiation in combined treatment of stage IV prostate cancer].
    Aleksandrov VP; Kondrat'eva EA; Karelin MI; Konnov BA; Zharinov GM; Metelev VV; Pecherskiĭ AV
    Urologiia; 1999; (6):26-8. PubMed ID: 16859000
    [No Abstract]   [Full Text] [Related]  

  • 20. Changes in chromogranin a serum levels during endocrine therapy in metastatic prostate cancer patients.
    Sasaki T; Komiya A; Suzuki H; Shimbo M; Ueda T; Akakura K; Ichikawa T
    Eur Urol; 2005 Aug; 48(2):224-9; discussion 229-30. PubMed ID: 16005374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.